Cytonics Corporation and Astaria Global Announce an Exclusive Licensing Agreement

October 9, 2019
Jupiter, FL:
Cytonics Corporation, a biotechnology company focused on developing therapies for osteoarthritis (OA), today announced it has entered into an exclusive licensing agreement with Astaria Global LLC, a medical device manufacturer and distributor in the veterinary market. Under the terms of the agreement, Astaria Global will acquire the rights to Cytonics’ patented Autologous Platelet Integrated Concentrate (APICTM) system, including subsequent autologous therapies specific in the treatment of pain, inflammation, the degeneration of joints and osteoarthritic pain for the equine and companion animal marketplace. Although the full terms of the deal were not disclosed, details did include that Astaria Global will pay Cytonics an initial fee for the rights to the exclusive license and then future royalties based on gross sales in the veterinary market. Astaria Global will introduce their veterinarian-modified version of the APICTM system in the fourth quarter of 2019 under the Alpha2 Regenerative Therapies brand to include Alpha2EQTM for horses and Alpha2CPTM for companion animals. Astaria Global is currently conducting a plasma technology study at Boise State University to quantify the level of Alpha-2-Macroglobulin concentrate over the leading competitor and establish a baseline for future studies specific for preventative therapies.

Astaria Global’s dedicated team of industry professionals apply science and international resources to bring advance regenerative therapies and unique products into the veterinarian marketplace. The company is committed to helping make a meaningful difference in the lives of the animals that their products touch, both for performance and well-being. Astaria Global is committed to the principles of sustainable development, and stand behind their brands with integrity and reliability throughout the world. Visit for more information.

We are thrilled to work with Astaria Global and truly believe that the company has the operational expertise needed to establish APICTM as the standard of care in the equine and companion animal marketplace. We have already developed a strong expertise and presence in the human treatment market and the additional line of Alpha2 Regenerative Therapies into this portfolio will allow us to strengthen our commercial presence.

Joey Bose, President of Cytonics

Our mission is to provide world-class regenerative therapies essential for our veterinarians and their clients to ensure that their animals live life to the fullest. This advanced plasma technology is the non-pharma, non-surgical option that has proven to be clinically effective, as well as cost-effective to administer.

Bill Cramer, Executive Director of Astaria Global

About Cytonics:

Cytonics, founded in 2006, is a private research and development company focusing on molecular diagnostic and therapeutic products for chronic musculoskeletal diseases. The company developed the FACT diagnostic test which helps identify the source of back and joint pain and assists physicians in determining the most appropriate treatment. Cleared in January of 2014, Cytonics developed the Autologous Platelet-Integrated Concentrate (APIC) System as a platelet-rich-plasma (PRP) device. In addition, the company also developed autologous cell-free A2M
concentrate and other forms of A2M therapeutics, including optimized recombinant forms. The company is currently pursuing pre-clinical studies for their lead recombinant A2M candidate, Cyt-108.

658 W. Indiantown Rd. Suite 214
Jupiter, FL 33458